RESUMEN
Estradiol and triphenylethylene antiestrogen actions have been studied extensively in breast cancer cell lines. However, their effects are still poorly understood on normal human breast cells. We have developed a culture system of normal human breast epithelial (HBE) cells. It has been shown previously that cultured HBE cells were hormone dependent and well adapted for the study of hormone/antihormone actions. However, until now, no data were available on estradiol receptor (ER) in HBE cells. In this study, the presence of ER was demonstrated by (a) whole-cell biochemical assay on breast cells after enzymatic tissue dissociation and (b) an immunocytochemical method using an anti-ER monoclonal antibody both on enzymatically dissociated cells and on 8-day cultured cells. Immunostaining was nuclear and cell positivity was heterogeneous. However, the percentage of positive cells and staining intensity were far greater in the presence of estradiol in the culture, indicating estradiol stimulation of ER. Moreover, HBE cells were used to study the action on cell growth of estradiol versus trans-tamoxifen (TAM), trans-4-hydroxytamoxifen (trans-4OHTAM), and cis-4-hydroxytamoxifen (cis-4OHTAM) alone or added to estradiol. Cell growth was estimated daily by a histometric method and by DNA assay at the end of the 7-day study. When the medium was minimally supplemented with human serum (1%), estradiol stimulated cell growth in a dose-dependent manner at concentrations varying from 10(-9) to 10(-7) M. TAM and trans-4OHTAM clearly inhibited mammary cell division when estradiol was added to the medium and, to a lesser extent, in the absence of estradiol. This inhibitory effect was dose dependent. trans-4OHTAM was 100 times more active than trans-TAM. cis-4OHTAM also clearly inhibited breast cell division at 10(-7) and 10(-6) M concentrations but was 3-fold less efficient than trans-4OHTAM. In conclusion, (a) the presence and estradiol dependence of ER have been demonstrated in HBE cells, which constitute a fruitful model for the study of hormone/antihormone actions, and (b) in these normal cells, estradiol stimulates growth, whereas TAM and the 4OHTAM isomers are potent inhibitors of cell multiplication, as they are in breast cancer cell lines in culture.
Asunto(s)
Mama/efectos de los fármacos , Estradiol/farmacología , Tamoxifeno/análogos & derivados , Tamoxifeno/farmacología , Mama/citología , División Celular/efectos de los fármacos , Células Cultivadas , ADN/análisis , Epitelio/efectos de los fármacos , Femenino , Humanos , Técnicas para Inmunoenzimas , Inmunohistoquímica , IsomerismoRESUMEN
The estradiol (E2) and progesterone (P) receptors (ER and PR) were studied in normal human breast epithelial (HBE) cells and fibroblasts cultured separately in our laboratory from surgical reductive mammoplasty samples. Immunocytochemical studies were performed on cytospun cells using the anti-ER antibody H222 Sp gamma and the anti-PR antibodies JZB39 and KD68. A specific immunostaining was observed for ER and PR in HBE cells. This immunostaining was nuclear, varying from cell to cell in positivity and intensity of staining. Moreover, ER and PR immunostaining was hormone-modulated: it increased in E2-treated cells and decreased after addition of the progestin R5020. In fibroblasts, a weak ER immunostaining and a stronger PR immunostaining could be observed; however it was not modified by either E2 or progestogen treatment. Thus, in normal breast epithelial cells, E2 stimulates both its own receptor and PR, whereas the progestin R5020 lowers ER and PR content. In contrast, ER and PR content in normal breast fibroblasts seem to be independent of E2 or P action.
Asunto(s)
Mama/química , Fibroblastos/química , Receptores de Estradiol/análisis , Receptores de Progesterona/análisis , Adolescente , Adulto , Células Cultivadas , Epitelio/química , Estradiol/farmacología , Femenino , Humanos , Inmunohistoquímica , Promegestona/farmacología , Receptores de Progesterona/efectos de los fármacosRESUMEN
OBJECTIVE: The efficacy and safety of chlormadinone acetate (CA) versus micronized progesterone (P) were assessed in non-hysterectomized postmenopausal women. MATERIALS AND METHODS: This was a multicenter, randomized, parallel group study with a 6-month double-blind period followed by a 12-month open period. Patients were randomized to receive every month during 18 months percutaneous 17 beta-estradiol (E(2)) 1.5 mg/day from Day 1 to 24 of treatment cycle, combined from Day 11 to 24 to either CA 10 mg/day (n=167) or P 200 mg/day (n=169). Endometrial biopsy (EB, main analysis criterion) was performed at baseline, and at Day 18-24 of the 6th and 18th cycles. RESULTS: At Month 6, EB did not evidence any hyperplasia. EB were inadequate for assessment in 24.5% and 47.5% of patients in the CA and MP groups, respectively. CA was found to be as protective as P (96.3% and 92.0% of success). However, the hormonal status of the endometrium differed (P<0.001): a secretory endometrium was found in 81.5% of the CA patients, compared to 50.7% in the P group. These transformations resulted in predictable, cyclic bleeding in 94.5% of the CA patients, compared to only 62.3% of the P patients (P=0.0001). Unscheduled bleeding, spotting and/or metrorrhagia, were more frequent under P than under CA (17.9% and 13.7%, respectively). The beneficial effects on hot flushes were more important in the CA group than in the P (P<0.001). At Month 18, the biopsy and clinical results were similar to those obtained at Month 6. The safety profile, particularly the lipid one, was similar in both groups, except for drowsiness and dizziness, which were significantly more frequent under P than under CA. CONCLUSION: The progestative effects of CA on the endometrium and on menopause-related symptoms were at least as good as those of P. Moreover, CA resulted more often than P in secretory effects, and in satisfying bleeding patterns.
Asunto(s)
Acetato de Clormadinona/administración & dosificación , Terapia de Reemplazo de Estrógeno , Menopausia/efectos de los fármacos , Congéneres de la Progesterona/administración & dosificación , Progesterona/administración & dosificación , Biopsia , Acetato de Clormadinona/efectos adversos , Colesterol/sangre , Mareo/inducido químicamente , Quimioterapia Combinada , Endometrio/efectos de los fármacos , Endometrio/patología , Estradiol/administración & dosificación , Femenino , Humanos , Persona de Mediana Edad , Progesterona/efectos adversos , Congéneres de la Progesterona/efectos adversos , Fases del Sueño , Triglicéridos/sangre , Hemorragia Uterina/epidemiologíaRESUMEN
OBJECTIVES: To determine the endometrial response in postmenopausal women treated with a sequential hormone replacement therapy (HRT) of estradiol and, either chlormadinone acetate (CA) or micronized progesterone (MP). METHODS: Three hundred and thirty-six postmenopausal women with a normal endometrium were randomized in the double-blind study. All patients received percutaneous estradiol 1.5 mg/day from day 1 to day 24 and either CA 10 mg/day or oral MP 200 mg/day from day 10 to day 24. The total duration of treatment was 18 months. Endometrial biopsies were performed before treatment and between day 18 and day 24 of the 18th month of HRT. RESULTS: Of the 336 patients selected, 317 had a biopsy at inclusion. Of them, 244 patients (124 in the CA group and 120 in the P group) were suitable for evaluation for analysis at the 18th month. Insufficient sampling occurred in 33.9% in the CA group and 60% in the MP group (probably atrophic). No case of hyperplasia could be reported in both groups. The endometrium was atrophic in 19.5 versus 27.1%, proliferative in 3.7 versus 8.3% and secretory in 76.8 versus 62.5% in CA and MP groups, respectively. It was possible to see histological differences induced by the two progestins. The CA endometria showed fewer glands lined by a cubo-cylindrical epithelium, with an edematous stroma, compared to the MP endometria which had more glands lined by a cylindrical epithelium, stroma being poorly edematous. These figures varied in intensity due to the length of progestative impregnation, predecidualization occurring later in the CA group, with distended capillaries. CONCLUSIONS: These results show that CA 10 mg/day is a powerful progestin compared to MP 200 mg/day, on weakly estradiol-primed endometria, giving a molecule-specific histological aspect with a good endometrial safety.
Asunto(s)
Acetato de Clormadinona/farmacología , Endometrio/efectos de los fármacos , Estradiol/farmacología , Terapia de Reemplazo de Hormonas , Progesterona/farmacología , Administración Cutánea , Administración Oral , Acetato de Clormadinona/administración & dosificación , Método Doble Ciego , Esquema de Medicación , Endometrio/patología , Estradiol/administración & dosificación , Femenino , Humanos , Persona de Mediana Edad , Posmenopausia , Progesterona/administración & dosificaciónRESUMEN
Progesterone (P), the natural hormone, binds to its specific receptors to induce specific progestational effects. In addition to this binding, P is able to interfere with the binding sites of other steroids. Therefore the natural hormone exhibits an anti-estrogenic activity, and anti-androgenic activity and also exerts anti-mineralocorticoid effects. For a long time progesterone could not be used in clinical applications because of a rapid liver inactivation after oral administration. An oral micronized preparation of progesterone is now available which produces adequate plasma and tissue levels of progesterone. The preparation reproduces the anti-estrogenic effect of the natural hormone on the endometrium at the dose of 200 mg daily. It also reproduces the anti-mineralocorticoid effect and has no androgenic action. No side effects have been reported as far as lipids profile, coagulation factors and blood pressure are concerned. Therefore oral micronized progesterone appears suitable for hormonal replacement therapy in various areas, essentially postmenopause therapy, premenstrual syndrome, correction of irregular cycles and pregnancy maintenance.
Asunto(s)
Progesterona/administración & dosificación , Administración Oral , Antagonistas de Estrógenos , Femenino , Humanos , Menopausia/efectos de los fármacos , Mineralocorticoides/antagonistas & inhibidores , Trabajo de Parto Prematuro/prevención & control , Embarazo , Síndrome Premenstrual/tratamiento farmacológico , Progesterona/efectos adversos , Progesterona/farmacocinética , Progesterona/farmacologíaRESUMEN
RU486, a potent antiprogesterone steroid was administered to 124 women requesting therapeutic abortion. All were less than 49 days from their last menstrual period. Ten of these subjects (Group I) received high doses of RU486 in a decremental dose regimen (400, 300, 200 and 100 mg/day) over 4 successive days and 14 received 50 mg/day for 7 days (Group II). A further 50 subjects (Group III) received 100 mg/day for seven days and the remaining 50 subjects (Group IV) received 450 mg in a single dose. In the first three groups, half the daily dose was given in the morning and the remainder in the evening. Blood was collected before, and on Days 4 and 7 and then once a week after commencing therapy until disappearance of circulating beta HCG. In addition to beta HCG, estradiol-17 beta (E2), progesterone (P), cortisol, and various metabolic and hematological parameters were measured. Plasma RU486 concentrations were also assayed in Group II, III and IV subjects on Day 7 of therapy and in some cases on Days 14 and 21. Ultrasonography was performed in all cases on Day 1 and on Day 14. All the patients bled within five days following RU486 administration, for 1 to 21 days. A complete abortion occurred in 60% in Group I, 50% in Group II, 86% in Group III, and 80% in Group IV. The difference between the last two groups and the first two was significant at p less than 0.01. The non-responders were submitted to a uterine vacuum aspiration. A stepwise discriminant analysis was performed and indicated that the best predictors of the outcome of therapy were beta HCG values and the gestational sac diameter. With these criteria, the prediction was accurate in 86.4% of the cases. The best results were obtained in the cases where the ultrasonic measurement of gestational sac was under 10 mm in diameter and the initial beta HCG values under 15,000 mIU/ml. Among the observed side effects were moderate pelvic cramps (20.9%), nausea (27%), fainting (4.8%); 61.3% of the women complained of fatigue. Heavy bleeding occurred in 15.3% of the women but only one of them required blood transfusion. In the patients with complete abortion, beta HCG values decreased to below 500 mIU/ml by Day 14 (but in 11 cases values fell below 2,000 mIU/ml only by Day 21). Plasma estradiol and progesterone also fell. Cortisol levels increased during therapy especially in subjects of Group I, but returned to basal values after termination of treatment.(ABSTRACT TRUNCATED AT 400 WORDS)
Asunto(s)
Abortivos , Mifepristona/farmacología , Abortivos/farmacología , Aborto Terapéutico/métodos , Administración Oral , Gonadotropina Coriónica/análisis , Decidua/citología , Relación Dosis-Respuesta a Droga , Estradiol/sangre , Estudios de Evaluación como Asunto , Femenino , Humanos , Hidrocortisona/sangre , Mifepristona/administración & dosificación , Mifepristona/efectos adversos , Embarazo , Progesterona/sangreAsunto(s)
Amenorrea/etiología , Ovario/anomalías , Adulto , Amenorrea/sangre , Amenorrea/tratamiento farmacológico , Amenorrea/inmunología , Anticuerpos/análisis , Etinilestradiol/administración & dosificación , Femenino , Hormona Folículo Estimulante/sangre , Gonadotropinas/orina , Humanos , Hormona Luteinizante/sangre , Ovario/inmunologíaAsunto(s)
Bocio/patología , Glándula Tiroides/patología , Adulto , Anciano , Autorradiografía , Coloides , Femenino , Histocitoquímica , Humanos , Persona de Mediana Edad , Ácido PeryódicoAsunto(s)
Enfermedad de Graves/patología , Adulto , Anciano , Autorradiografía , Femenino , Humanos , Técnicas In Vitro , Masculino , Persona de Mediana EdadRESUMEN
Two hundred and forty end-stage kidneys removed during transplantation, were studied by immunofluorescence. Mesangial IgA glomerulonephritis was demonstrated in 24 cases. Since mesangial IgA glomerulonephritis accounts for 10% of the cases of terminal renal failure requiring transplantation, its prognosis is not as mild as it was initially believed. About one third of the patients must eventually develop renal insufficiency. Such an unfavourable course is even possible when the disease began during childhood.
Asunto(s)
Lesión Renal Aguda/etiología , Glomerulonefritis/complicaciones , Inmunoglobulina A , Lesión Renal Aguda/mortalidad , Adolescente , Adulto , Envejecimiento , Niño , Femenino , Técnica del Anticuerpo Fluorescente , Glomerulonefritis/diagnóstico , Humanos , Trasplante de Riñón , MasculinoRESUMEN
Deposits with IgA as the main component frequently are found in the glomeruli of patients with cirrhosis of the liver. These deposits usually are latent. In some cases, however, they may be associated with proliferative changes and clinical manifestations of glomerular involvement.
Asunto(s)
Glomerulonefritis/etiología , Glomérulos Renales/patología , Cirrosis Hepática/complicaciones , Adulto , Anciano , Femenino , Glomerulonefritis/inmunología , Glomerulonefritis/patología , Humanos , Inmunoglobulina A , Inmunoglobulina G , Inmunoglobulina M , Glomérulos Renales/inmunología , Cirrosis Hepática/inmunología , Cirrosis Hepática/patología , Masculino , Persona de Mediana EdadRESUMEN
Bcl-2 is a proto-oncogene initially described in the (14;18) translocation in follicular lymphoma. It has been shown to prolong cell survival by preventing apoptosis. Endometrium undergoes rapid proliferation and differentiation under hormone control and is thus an excellent model to study the hormone dependency of Bcl-2 expression. We studied Bcl-2 expression by an immunohistochemical method in 53 samples of normal endometrium randomly distributed throughout the menstrual cycle, as well as five samples of hyperplastic endometrium. Bcl-2 staining predominated in glandular cells and peaked at the end of the follicular phase. Bcl-2 expression disappeared at the onset of secretory activity. The stroma, surface lining epithelium and arterial vessels also displayed cyclic variations in Bcl-2 expression. These results strongly suggest hormone-dependent regulation of Bcl-2 expression, which could play an important role in tumorigenesis.
Asunto(s)
Endometrio/química , Ciclo Menstrual/fisiología , Proteínas Proto-Oncogénicas/análisis , Adulto , División Celular/fisiología , Endometrio/metabolismo , Endometrio/fisiología , Femenino , Fase Folicular/metabolismo , Fase Folicular/fisiología , Humanos , Hiperplasia/patología , Inmunohistoquímica , Antígeno Ki-67 , Fase Luteínica/metabolismo , Fase Luteínica/fisiología , Persona de Mediana Edad , Miometrio/química , Miometrio/metabolismo , Miometrio/fisiología , Proteínas de Neoplasias/análisis , Proteínas Nucleares/análisis , Proto-Oncogenes Mas , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas/fisiología , Proteínas Proto-Oncogénicas c-bcl-2RESUMEN
The embryonic testicular regression syndrome associated with severe mental retardation is reported in three 46,XY sibs each of whom has a 46,XY chromosome complement. A fourth sib, a sister, also is severely retarded mentally; her chromosome complement is 46,XX. The 46,XY individuals, who were raised as females, presented varying degrees of genital ambiguity, indicating that their gonadal activities had been arrested at different times during embryogenesis. No trace of gonadal tissue could be found in either patient. The coincidence of the embryonic testicular regression syndrome and severe mental retardation in the same sibship is discussed.